DB:2UV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Applied Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2UV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-16.8%

2UV

-0.07%

DE Biotechs

1.5%

DE Market


1 Year Return

336.5%

2UV

9.3%

DE Biotechs

-1.8%

DE Market

Return vs Industry: 2UV exceeded the German Biotechs industry which returned 8.7% over the past year.

Return vs Market: 2UV exceeded the German Market which returned -0.7% over the past year.


Shareholder returns

2UVIndustryMarket
7 Day-16.8%-0.07%1.5%
30 Day-23.7%-0.9%4.3%
90 Day12.9%20.8%25.1%
1 Year336.5%336.5%9.6%9.3%0.2%-1.8%
3 Yearn/a15.5%14.7%1.3%-6.9%
5 Yearn/a20.9%18.9%15.0%-0.2%

Price Volatility Vs. Market

How volatile is Applied Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Applied Therapeutics undervalued compared to its fair value and its price relative to the market?

48.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2UV (€31.6) is trading below our estimate of fair value (€61.47)

Significantly Below Fair Value: 2UV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2UV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2UV is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2UV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2UV is overvalued based on its PB Ratio (5x) compared to the DE Biotechs industry average (3.9x).


Next Steps

Future Growth

How is Applied Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

3.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2UV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2UV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2UV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2UV's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 2UV's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2UV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Applied Therapeutics performed over the past 5 years?

-113.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2UV is currently unprofitable.

Growing Profit Margin: 2UV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2UV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 2UV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2UV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).


Return on Equity

High ROE: 2UV has a negative Return on Equity (-31.54%), as it is currently unprofitable.


Next Steps

Financial Health

How is Applied Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 2UV's short term assets ($163.7M) exceed its short term liabilities ($8.5M).

Long Term Liabilities: 2UV's short term assets ($163.7M) exceed its long term liabilities ($1.6M).


Debt to Equity History and Analysis

Debt Level: 2UV is debt free.

Reducing Debt: 2UV has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2UV has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 2UV has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 80.3% each year.


Next Steps

Dividend

What is Applied Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2UV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2UV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2UV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2UV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2UV's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Shoshana Shendelman (41yo)

no data

Tenure

US$11,589,972

Compensation

Dr. Shoshana Shendelman, PhD is the Founder of Applied Therapeutics Inc. and serves as its Chairman, President, Chief Executive Officer and Secretary. Dr. Shendelman has been Director of Applied Therapeuti ...


CEO Compensation Analysis

Compensation vs Market: Shoshana's total compensation ($USD11.59M) is above average for companies of similar size in the German market ($USD1.41M).

Compensation vs Earnings: Shoshana's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Shoshana Shendelman
Chairmanno dataUS$11.59m14.94% $106.1m
Riccardo Perfetti
Chief Medical Officer1.92yrsUS$3.36mno data
Charles Silberstein
CFO & Head of Business Development0.17yrno datano data
Chids Mahadevan
VP of Finance & Chief Accounting Officer0.58yrno data0.00011% $781.1
Adam Hansard
Chief Commercial Officer0.33yrno datano data

0.5yrs

Average Tenure

51yo

Average Age

Experienced Management: 2UV's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Shoshana Shendelman
Chairmanno dataUS$11.59m14.94% $106.1m
Jay Skyler
Independent Director1.25yrsUS$160.63kno data
Lawrence Steinman
Member of Scientific Advisory Boardno datano datano data
Teena Lerner
Independent Director3.33yrsUS$278.58k0.22% $1.6m
Stacy Kanter
Independent Director1.17yrsUS$164.27k0.029% $208.6k
Gregg Stone
Member of Scientific Advisory Boardno datano datano data
Donald Landry
Chairman of Scientific Advisory Boardno datano datano data
Roy Freeman
Member of Scientific Advisory Boardno datano datano data
Roxana Mehran
Member of Scientific Advisory Boardno datano datano data
Andrew Wasmuth
Member of Scientific Advisory Boardno datano datano data

1.3yrs

Average Tenure

63yo

Average Age

Experienced Board: 2UV's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 2UV insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.7%.


Top Shareholders

Company Information

Applied Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Applied Therapeutics, Inc.
  • Ticker: 2UV
  • Exchange: DB
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$799.782m
  • Listing Market Cap: US$710.127m
  • Shares outstanding: 22.12m
  • Website: https://www.appliedtherapeutics.com

Number of Employees


Location

  • Applied Therapeutics, Inc.
  • 545 Fifth Avenue
  • Suite 1400
  • New York
  • New York
  • 10017
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APLTNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2019
2UVDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2019

Biography

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company’s preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/01 21:58
End of Day Share Price2020/07/01 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.